Search
Search Results
-
Getting the Price Right: Lessons for Medicare Price Negotiation from Peer Countries
The USA pays more for brand-name prescription drugs than any other country and new legislation from August 2022 gives Medicare the authority to...
-
From Indication-Based Pricing to Blended Approach: Evidence on the Price and Reimbursement Negotiation in Italy
BackgroundNew indications for existing medicines are increasing over time. In most countries, drug pricing and reimbursement conditions are...
-
Health technology assessment and price negotiation alignment for rare disorder drugs in Canada: Who benefits?
BackgroundSince 2014, the Canadian Agency for Drugs and Technologies in Health (CADTH), which performs health technology assessments for all federal,...
-
Consumption and cost trends of EGFR TKIs: influences of reimbursement and national price negotiation
BackgroundEpidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been widely used in the treatment of EGFR mutation...
-
Examining confidential wholesale margin estimates in European countries for the price negotiation of patented drugs in Germany: a statistical model
BackgroundBased on the legal framework laid down in section 130b (9) of Book V of the German Social Code, various criteria are relevant for the...
-
Impact of national drug price negotiation policy on the accessibility and utilization of PCSK9 inhibitors in China: an interrupted time series analysis
BackgroundPCSK9 inhibitors are a novel class of lipid-lowering drugs that have demonstrated favorable efficacy and safety. Evolocumab and alirocumab...
-
Health technology assessment-informed pricing negotiation in China: higher negotiated price for more effective targeted anticancer medicines?
BackgroundIn China, health technology assessment (HTA) has recently been adopted in pricing negotiation for medicine listing in the National...
-
Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China
BackgroundHigh prices of anticancer medicines have increased the economic burden for both patients and health insurance systems. Since 2017, China...
-
The vacated space of volume/price of the drugs centralized procurement with quantity in secondary and above public hospitals of China
BackgroundIn 2018, the National Centralized Drug Procurement (NCDP) policy has been implemented in 11 provinces, and promoted across the country in...
-
-
Impact of medical insurance access negotiation on the utilization of innovative anticancer drugs in China: an interrupted time series analysis
BackgroundThe high costs of innovative anticancer drugs hinder a number of cancer patients’ access to these drugs in China. To address this problem,...
-
Assessing the price levels of medical service and influential factors: evidence from China
BackgroundMedical service prices play a crucial role in cost containment in China. This study aimed to assess the change in medical service price...
-
The usage and costs of national drug price-negotiated anticancer medicines in a first-tier city in Northeast China: a study based on health insurance data
BackgroundThe National Drug Price Negotiation (NDPN) policy has entered a normalisation stage, aiming to alleviate, to some extent, the...
-
Price setting in the Brazilian private health insurance sector
Brazil’s private health insurance market is the second largest in the world, behind only the United States, making it a valuable source of real-world...
-
Do Health Technology Assessment organisations consider manufacturers’ costs in relation to drug price? A study of reimbursement reports
IntroductionDrug reimbursement decisions are often made based on a price set by the manufacturer. In some cases, this price leads to public and...
-
Intellectual property and access to medicines: map** public attitudes toward pharmaceuticals during the United States-Mexico-Canada Agreement (USMCA) negotiation process
BackgroundTransparency and accountability are essential components at all stages of the trade negotiation process. This study evaluates the extent to...
-
Role of Economic Evaluations on Pricing of Medicines Reimbursed by the Italian National Health Service
ObjectiveThe main objective of this study was to explore the extent to which the incremental cost-effectiveness ratio (ICER), alongside other...
-
Food industry perspectives on potential policies targeting unhealthy food and beverage price promotions in Australian supermarkets
Current supermarket price promotions are likely to encourage unhealthy diets, leading some governments to recently endorse restrictions on price...
-
Spending, Utilization, and Price Trends for Immune Checkpoint Inhibitors in US Medicaid Programs: An Empirical Analysis from 2011 to 2021
Background and ObjectiveImmune checkpoint inhibitors (ICIs) have become a cornerstone in cancer treatment. With high treatment costs and an...
